NL0015000DX5
© Globe Newswire
23.12.2025
ATAI
LISTED
NASDAQ
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
News Preview
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2025
ATAI
LISTED
NASDAQ
Enhanced Fortifies Executive Leadership Team & Board of Directors
News Preview
– Co-Founder Maximilian Martin Appointed CEO –
– Co-Founder Christian Angermayer Appointed Executive Chairman –
– Jim Murren to join Board of Directors –
– Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
ATAI
LISTED
NASDAQ
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
News Preview
AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.11.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
News Preview
NEW YORK and AMSTERDAM, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the successful completion of the strategic com...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
20.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
News Preview
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Pricing of Public Offering of Common Shares
News Preview
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Proposed Public Offering of Common Shares
News Preview
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of its common shares. atai expects to grant...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
News Preview
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), and Beckley Psytech Limited (“Beckley Psytech”), who previously announced a planned strategic combination to create a global leader in transformative mental health therapies, today announced that the U.S. Food and Drug Administration...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
News Preview
NEW YORK and AMSTERDAM and OXFORD, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biop...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Awarded Grant from the National Institutes of Health
News Preview
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use dis...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
ATAI
LISTED
NASDAQ
atai Life Sciences to Participate in September Investor Conferences
News Preview
NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investo...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
News Preview
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.07.2025
ATAI
LISTED
NASDAQ
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
News Preview
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment as...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces $50 Million Private Placement Financing
News Preview
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, in...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
News Preview
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage bio...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
ATAI
LISTED
NASDAQ
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Atai Life Sciences N.V. (NASDAQ: ATAI) and Beckley Psytech Limited is fair to Atai shareholders.
Halper Sadeh encourages Atai shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
News Preview
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley”), a private clinical-stage bio...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
News Preview
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
News Preview
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
News Preview
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
News Preview
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.03.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
News Preview
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
ATAI
LISTED
NASDAQ
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
News Preview
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference i...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.02.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Pricing of Public Offering of Common Shares
News Preview
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. a...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
ATAI
LISTED
NASDAQ
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
News Preview
Q3 2024 earnings...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
ATAI
LISTED
NASDAQ
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
News Preview
atai Reports Q2 2024 Financial Results and Corporate Updates...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ATAI
LISTED
NASDAQ
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
News Preview
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2024
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
News Preview
NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial r...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.05.2024
ATAI
LISTED
NASDAQ
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
News Preview
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from Ju...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
ATAI
LISTED
NASDAQ
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
News Preview
NEW YORK and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced first quarter 2024 financial results, provided corporate updates and announced a transition in its leadership....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
